Vital Therapies Inc (NASDAQ:VTL)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $0.30, but opened at $0.31. Vital Therapies shares last traded at $0.30, with a volume of 77051 shares changing hands.

Several brokerages recently issued reports on VTL. William Blair upgraded Vital Therapies from a “market perform” rating to an “outperform” rating in a research note on Monday, August 6th. Cantor Fitzgerald lowered Vital Therapies from an “overweight” rating to a “neutral” rating in a research note on Wednesday, September 12th. BTIG Research restated a “hold” rating on shares of Vital Therapies in a research note on Thursday, August 9th. BidaskClub lowered Vital Therapies from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 16th. Finally, ValuEngine upgraded Vital Therapies from a “hold” rating to a “buy” rating in a research note on Friday, June 29th. Seven research analysts have rated the stock with a hold rating, Vital Therapies currently has an average rating of “Hold” and an average target price of $12.00.

The firm has a market cap of $11.67 million, a price-to-earnings ratio of -0.24 and a beta of 4.29.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. On average, equities analysts forecast that Vital Therapies Inc will post -1.11 EPS for the current fiscal year.

In other Vital Therapies news, Director Muneer A. Satter sold 11,382,277 shares of Vital Therapies stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $0.36, for a total transaction of $4,097,619.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Muneer A. Satter sold 447,500 shares of Vital Therapies stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $0.36, for a total value of $161,100.00. The disclosure for this sale can be found here. Insiders have sold 11,929,271 shares of company stock worth $4,292,912 over the last ninety days. Company insiders own 33.90% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in VTL. Citigroup Inc. boosted its holdings in shares of Vital Therapies by 1,093.5% in the 1st quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock worth $108,000 after acquiring an additional 14,576 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in shares of Vital Therapies in the 2nd quarter worth approximately $139,000. Rhumbline Advisers acquired a new position in shares of Vital Therapies in the 2nd quarter worth approximately $183,000. Element Capital Management LLC acquired a new position in shares of Vital Therapies in the 1st quarter worth approximately $209,000. Finally, TD Asset Management Inc. boosted its holdings in shares of Vital Therapies by 50.2% in the 2nd quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock worth $249,000 after acquiring an additional 12,144 shares in the last quarter. 32.62% of the stock is currently owned by institutional investors and hedge funds.

About Vital Therapies (NASDAQ:VTL)

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Featured Article: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.